China NMPA gives approval for Tildrakizumab injection to treat plaque psoriasis

Tildrakizumab injection is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

111
Approval approved
Picture: Pixabay

Last Updated on December 31, 2023 by The Health Master

Sun Pharmaceutical Industries announced that the New Drug Application (NDA) for Tildrakizumab injection under the brand name Ilumetri has been approved by the National Medical Products Administration of the People’s Republic of China (NMPA).

Tildrakizumab injection is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

In June 2019, Sun Pharma out-licensed tildrakizumab to a subsidiary of China Medical System Holdings Limited (CMS), for development, regulatory filings and commercialisation of the product in Greater China.

According to CMS, the results of the extended study of Phase III clinical trial in China demonstrated that the primary efficacy assessment indicator PASI 75 response rate continued to increase over the treatment time.

The PASI 75 response rate reached a high level after 28 weeks of treatment with ILUMETRI and maintained at 91.3 per cent at week 52, and Tildrakizumab injection (Ilumetri) showed good long-term safety and tolerance.

Tildrakizumab Injection has also been approved for marketing in the US, EU, Japan, UK, Switzerland, Canada, Australia, Hong Kong and other countries/regions under the brands of ILUMYA and ILUMETRI in different geographies.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news